SGR-1505 is under clinical development by Schrodinger and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGR-1505’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGR-1505 overview
SGR-1505 is under development for the treatment of BTK-resistant, refractory or relapsed B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia, MALT lymphoma, follicular lymphoma, Burkitt lymphoma, plasmablastic lymphoma, high-grade B-cell lymphoma, primary cutaneous follicle center lymphoma, primary effusion lymphoma, primary mediastinal large B cell lymphoma, T-cell/histiocyte rich lymphoma, ALK-positive large B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma splenic marginal zone lymphoma, nodal marginal zone lymphoma, HHV8-positive DLBCL and duodenal-type follicular lymphoma. It is administered through oral route in the form of tablet. The drug candidate acts by oncogenic activation of nuclear factor-kappa B which acts by targeting MALT1 activity. It is developed based on the Schrodinger artificial intelligence (AI) technology.
Schrodinger overview
Schrodinger is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. Schrodinger‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates through offices in the US, Germany, Japan, Ireland, the UK, India, China and South Korea. Schrodinger is headquartered in New York City, New York, the US.
For a complete picture of SGR-1505’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
